Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...

Investing.com -- Pfizer Inc. (NYSE: PFE) has temporarily avoided a standoff with activist investor Starboard Value LP.

It’s not just the tech billionaires descending on Washington. Plenty of chief executives from other industries are also ...

Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...

Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.

Purchase of Intra-Cellular will give J&J control of mental health drug Caplyta, which CEO predicts will become a $5 billion ...

Pfizer Chief Executive Albert Bourla says recent Seagen acquisition provides "tremendous opportunity for growth." This interview was recorded on Jan. 15, 2024, at the World Economic Forum meeting ...

Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...